We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex ... Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites. Show more
IRVINE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to...
Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and only FDA approved solution for the disease Demodex blepharitis impacts...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -5.79 | -15.1451739472 | 38.23 | 38.335 | 31.72 | 364574 | 34.73713906 | CS |
| 4 | -1.12 | -3.33730631704 | 33.56 | 38.46 | 31.72 | 566843 | 35.49774377 | CS |
| 12 | 6 | 22.6928895613 | 26.44 | 40.4 | 25.46 | 757155 | 33.26842462 | CS |
| 26 | 19.19 | 144.830188679 | 13.25 | 40.4 | 12.84 | 697327 | 26.0943126 | CS |
| 52 | 19.24 | 145.757575758 | 13.2 | 40.4 | 12.57 | 532310 | 23.05272373 | CS |
| 156 | 3.73 | 12.9919888541 | 28.71 | 40.4 | 10.8001 | 234208 | 21.65156775 | CS |
| 260 | 14.14 | 77.2677595628 | 18.3 | 63.69 | 10.8001 | 211214 | 22.34257606 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
